VivoSeq
Other

Lichen Planopilaris

9

Pipeline Programs↗

4

Active Trials↗

7

Companies Involved↗

Lichen Planopilaris is an early-stage landscape with 9 programs across 7 companies. The most active players are Eli Lilly, Novartis, AbbVie. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

15/100

Mech. Concentration

29/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

2 programs

Phase 1Novartis logo

Novartis

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

ApprovedRoche logo

Roche

1 program

ApprovedAlnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

2 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

6 of 9 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody333%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 82% of 11 pipeline programs.

Analysis

Trial Status

7

clinical trials

Recruiting3 · 43%
Completed3 · 43%
Not yet recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Lichen Planopilaris in Routine Clinical Care: a Patient Preference Trial
Recruiting·EErasmus Medical Center·N/A·NCT06512753·56 enrolled
Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
Recruiting·TThe Skin Center Dermatology Group·Phase 4·NCT07396168·10 enrolled
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris
Recruiting·PPriovant Therapeutics, Inc.·Preclinical·NCT07532603·342 enrolled
Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.
Not yet recruiting·—·Phase 2·NCT07492251·56 enrolled
Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris
Completed·UUniversity of New Mexico·Phase 1·NCT05030415·9 enrolled
Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
Completed·WWashington University School of Medicine·Phase 2·NCT04409041·43 enrolled
Valchlor in the Treatment of Lichen Planopilaris
Completed·MMayo Clinic·Phase 2·NCT03417141·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)